KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Invested Capital data on record, last reported at -$13.0 million in Q4 2025.

  • For Q4 2025, Invested Capital rose 73.77% year-over-year to -$13.0 million; the TTM value through Dec 2025 reached -$13.0 million, up 73.77%, while the annual FY2025 figure was -$13.0 million, 73.77% up from the prior year.
  • Invested Capital reached -$13.0 million in Q4 2025 per AMRX's latest filing, down from $2.5 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $3.1 billion in Q4 2021 and bottomed at -$49.4 million in Q4 2024.
  • Average Invested Capital over 5 years is $1.9 billion, with a median of $2.3 billion recorded in 2024.
  • Peak YoY movement for Invested Capital: soared 649.92% in 2021, then plummeted 102.02% in 2024.
  • A 5-year view of Invested Capital shows it stood at $3.1 billion in 2021, then dropped by 8.83% to $2.8 billion in 2022, then fell by 13.04% to $2.4 billion in 2023, then tumbled by 102.02% to -$49.4 million in 2024, then soared by 73.77% to -$13.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were -$13.0 million in Q4 2025, $2.5 billion in Q3 2025, and $2.1 billion in Q2 2025.